BioCentury | Jul 11, 2018
Translation in Brief

Poisoning the stromal chalice

...Croix’s 2012 Cancer Cell paper that used a mAb against a stroma-enriched antigen, anthrax toxin receptor 1 (ANTXR1; TEM8...
...deplete tumor stroma and starve tumor cells (see “A TEM To Kill” ). While the ANTXR1-targeted...
...the ANTXR1 ADC caused no observable on-target, off-tumor toxicities in treated mice. Mice unresponsive to ANTXR1-targeted...
BioCentury | Jun 13, 2018
Distillery Therapeutics

Cancer

...cancer; colorectal cancer; breast cancer; lung cancer; ovarian cancer Patient sample and mouse studies suggest anti-ANTXR1...
...esophageal, kidney, uterine, colorectal, breast, lung, ovarian and pancreatic cancer patients, tumor stroma levels of ANTXR1...
...treat non-small cell lung cancer (NSCLC) and breast, ovarian and pancreatic cancers. TARGET/MARKER/PATHWAY: Anthrax toxin receptor 1 (ANTXR1; TEM8...
BioCentury | May 2, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling Tumor mutations of 22 genes could help diagnose prostate cancer, and mutations in two of them could help predict patient outcomes. Whole-genome sequencing of 112 primary and metastatic prostate cancer and matched...
BioCentury | Dec 5, 2017
Distillery Therapeutics

Cancer

...cells targeting ANTXR1 could help treat triple-negative breast cancer (TNBC). In patient samples, levels of ANTXR1...
...in tumors than in adjacent normal breast tissue. In co-culture with four TNBC cell lines, anti-ANTXR1...
...could include clinical testing of the anti-ANTXR1 CAR T cells in TNBC. TARGET/MARKER/PATHWAY: Anthrax toxin receptor 1 (ANTXR1; TEM8...
BioCentury | Jun 20, 2017
Distillery Therapeutics

Other

INDICATION: Genetic disorders Patient sample and mouse studies suggest inhibiting COL6A1 could help treat hyaline fibromatosis syndrome (HFS), which is caused by ANTXR2 mutations. In patients, levels of COL6A1 were higher in HFS skin nodules...
BioCentury | Nov 2, 2016
Distillery Techniques

Other

TECHNOLOGY: Computational models A computational model for predicting how mutations alter activity could aid the design of therapies that overcome drug resistance. For any protein-compound pair, the model utilizes molecular dynamic simulations to build a...
BioCentury | Jul 9, 2015
Distillery Therapeutics

Therapeutics: Ras homolog enriched in striatum (RHES; RASD2; TEM2)

Neurology INDICATION: Huntington's disease (HD) Mouse studies suggest inhibiting RHES in the brain could help treat HD. In a transgenic mouse model of HD expressing mutant huntingtin (HTT) , systemic homozygous and heterozygous knockout of RHES...
BioCentury | Jan 22, 2015
Distillery Therapeutics

Therapeutics: Mammalian target of rapamycin complex 1 (mTORC1); RASD family member 2 (RASD2; Rhes; TEM2)

Neurology INDICATION: Huntington's disease (HD) Studies in patient samples and mice suggest increasing mTORC1 signaling could help treat HD. In striatal tissues samples from HD patients and a mouse model of HD, mTORC1 activity was...
BioCentury | Apr 24, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer CD248 endosialin (TEM1) Mouse studies suggest a DNA plasmid encoding a TEM1-tetanus toxoid (TT) fusion peptide could be used as a cancer vaccine. TEM1...
BioCentury | Apr 17, 2014
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Tumor endothelial marker (TEM)-expressing circulating endothelial cells (CECs) as a blood-based marker to detect tumors and monitor response to antiangiogenic therapy Studies in human...
Items per page:
1 - 10 of 38